Evidence map›Paper›PMID 39030327›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss.

Methma Udawatta, Nicholas Fidalgo, Farrah J Mateen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07207148 (People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07207148 recruitingnot on this map

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

TypeobservationalSponsorNorthwestern UniversityRan2025 to 2028Enrolled100ConditionsMultiple SclerosisArmsGLP-1, Ocrelizumab (US)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Methma UdawattaDepartment of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Nicholas FidalgoDepartment of Neurology, Massachusetts General Hospital, 165 Cambridge Street, #627, Boston, MA, 02114, USA.
Farrah J MateenDepartment of Neurology, Massachusetts General Hospital, 165 Cambridge Street, #627, Boston, MA, 02114, USA. fmateen@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-4293-8115

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a risk factor for developing and worsening multiple sclerosis (MS) and is often comorbid with MS, exacerbating disability. We retrospectively studied MS patients starting glucagon-like peptide-1 (GLP-1) agonists at the [redacted for review] U.S.A. (January 2005-June 2024). Patients (n = 49) were mostly female (73%), average age 54 years old, with relapsing disease (78%) and an average starting body mass index (BMI) of 39.7 kg/m

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsMultiple SclerosisObesityWeight LossAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesGlucagon-Like Peptide-1 Receptor AgonistsBody mass indexComorbidityGlucagon-like peptide-1 receptor agonistMultiple sclerosisObesityWeight loss

Identifiers

PMID39030327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.